Stocks Health care PCRX
NASDAQ · Health carePacira BioSciences, Inc. (PCRX)
Pacira BioSciences, Inc. brought in $743.3M of revenue over the twelve months to September 30, 2026, up 3.7% from a year earlier. Net income was $37.7M, a net margin of 5.1%. Operating cash flow minus capital spending left $136.7M of free cash flow in fiscal 2025. At September 30, 2026 it held $247M in cash against $293.6M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Pacira BioSciences, Inc.
- Net worth
- Pacira BioSciences, Inc. has a market value (market cap) of $1.5B at the latest share price, and shareholders' equity of $712.3M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $726.4M (+3.6% year on year), with net income of $7M. Over the 12 months to September 30, 2026: revenue $743.3M, net income $37.7M.
- Cash flow
- In fiscal 2025 operations brought in $152M of cash; after $15.3M of capital spending, free cash flow was $136.7M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
What Pacira BioSciences, Inc. does
Pacira BioSciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PCRX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $726.4M | $7M | $0.16 | $136.7M |
| 2024 | $701M | -$99.6M | -$2.15 | $178.8M |
| 2023 | $675M | $42M | $0.89 | $139.5M |
| 2022 | $666.8M | $15.9M | $0.34 | $115.2M |
| 2021 | $541.5M | $42M | $0.92 | $79.9M |
| 2020 | $429.6M | $145.5M | $3.33 | $39.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where PCRX ranks in Health care
Latest SEC filings
What Pacira BioSciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue fell 1.6% to $176.7M versus the same quarter last year; diluted EPS $0.70 versus $0.12.
- November 5, 2026
- November 3, 2026Response to tender offer (amended) SC 14D9/A
- October 30, 2026Passive stake changed SCHEDULE 13G/A
- October 30, 2026Response to tender offer SC 14D9
- October 13, 2026Activist stake changed SCHEDULE 13D/A
- October 8, 2026Form SC14D9C filing SC14D9C
- October 8, 2026Material agreement8-KPacira BioSciences entered into an agreement to be acquired by Viatris for $36.50 per share in cash.
- August 7, 2026Passive stake (5% or more) SCHEDULE 13G
- August 4, 2026
What is PCRX worth? A DCF from its reported cash flow
Insider trades
What the people running Pacira BioSciences, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $288.5K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 30, 2026 | Cross ShawnChief Financial Officer | Shares withheld for tax | 9,540 | $347.2K |
| October 8, 2026 | Riker LaurenSenior Vice President, Finance | Exercised options | 6,000 | $194.1K |
| October 8, 2026 | Riker LaurenSenior Vice President, Finance | Soldpre-planned (10b5-1) | 6,000 | $217.9K |
| August 17, 2026 | Slonin JonathanChief Medical Officer | Soldpre-planned (10b5-1) | 3,040 | $70.6K |
| June 11, 2026 | Riker LaurenSenior Vice President, Finance | Soldpre-planned (10b5-1) | 6,115 | $143.7K |
| June 10, 2026 | Brege LauraDirector | Received as pay | 6,405 | - |
| June 10, 2026 | Froimson MarkDirector | Received as pay | 6,405 | - |
| June 10, 2026 | Bigal MarceloDirector | Received as pay | 6,405 | - |
Who owns PCRX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Vanguard Portfolio Management13G, passive | 6.38% | May 1, 2026 |
| Vanguard Capital Management13G, passive | 5.15% | May 1, 2026 |
| Dimensional Fund Advisors LP13G, passive | 5.1% | April 9, 2026 |
Largest institutional holders
Insiders
14 insiders reported holding 1,475,880 shares in total, about $53.9M at the last price.
| Holder | Shares |
|---|---|
| Lee Frank D.Chief Executive Officer, Director | 660,831 |
| Slonin JonathanChief Medical Officer | 216,384 |
| Williams KristenChief Administrative Officer | 167,062 |
| Teehan BrendanChief Commercial Officer | 100,934 |
| Cross ShawnChief Financial Officer | 95,801 |
| Riker LaurenSenior Vice President, Finance | 62,284 |
| Kronenfeld Mark A.Director | 31,065 |
| Brege LauraDirector | 30,120 |
| Froimson MarkDirector | 26,541 |
| Christie ChristopherDirector | 23,059 |
Questions about PCRX
What does Pacira BioSciences, Inc. do?
Pacira BioSciences, Inc. is a company in the Health care sector, listed on NASDAQ as PCRX. Its shares trade on NASDAQ under the ticker PCRX.
What is Pacira BioSciences, Inc.'s net worth?
Pacira BioSciences, Inc. has a market value (market cap) of $1.5B at the latest share price, and shareholders' equity of $712.3M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Pacira BioSciences, Inc. profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $37.7M on revenue of $743.3M, a net margin of 5.1%.
How much revenue does Pacira BioSciences, Inc. make?
Over the twelve months to September 30, 2026 Pacira BioSciences, Inc. reported revenue of $743.3M. That is 3.7% more than a year earlier.
When did Pacira BioSciences, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
Similar companies
Compare PCRX with
Follow PCRX
Get an email when Pacira BioSciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Pacira BioSciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.